# Clinical Feasibility of Speech Phenotyping for Remote Assessment of Neurodegenerative and Psychiatric Disorders

> **NCT04939818** · — · COMPLETED · sponsor: **Novoic Limited** · enrollment: 172 (actual)

## Conditions studied

- Alzheimer Disease
- Mild Cognitive Impairment
- Dementia With Lewy Bodies
- Dementia, Vascular
- Frontotemporal Dementia
- Primary Progressive Aphasia
- Parkinson Disease
- Motor Neuron Disease
- Major Depressive Disorder
- Bipolar Disorder
- Amyotrophic Lateral Sclerosis

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT04939818
- **Lead sponsor:** Novoic Limited
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2021-06-14
- **Primary completion:** 2022-09-15
- **Final completion:** 2022-09-15
- **Target enrollment:** 172 (ACTUAL)
- **Last updated:** 2023-03-22

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04939818

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04939818, "Clinical Feasibility of Speech Phenotyping for Remote Assessment of Neurodegenerative and Psychiatric Disorders". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT04939818. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*